Novo Nordisk sticks to cautious obesity sales goal

Despite an optimistic stock market, Novo Nordisk is not changing its modest guidance of more than doubling its obesity drug sales by 2025.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

Novo Nordisk is stubbornly mantaining its cautious goal for obesity sales in spite of pervasive optimism on the stock market, according to Danish media Børsen.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading